

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 53 to 70 OF 2018**

Statements of Principles (SOPs) Nos. 53 to 70 of 2018 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 22 June 2018.

The Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). The day of commencement as specified in each of the Instruments is 23 July 2018. In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from: [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the new SOP template which commenced in 2015. This document is available on the Authority's website <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

2 July 2018

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Codes** |
| **REVOCATIONS** | | | |
|  |  |  |  |
| 53 & 54/2018 | bipolar disorder | 23/07/2018 | Nil |
|  |  |  |  |
| 55 & 56/2018 | panic disorder | 23/07/2018 | F40.01 or F41.0 |
|  |  |  |  |
| 57 & 58/2018 | cluster headache | 23/07/2018 | G44.0 |
|  |  |  |  |
| 59 & 60/2018 | macular degeneration | 23/07/2018 | Nil |
|  |  |  |  |
| 61 & 62/2018 | localised sclerosis | 23/07/2018 | L94.0 or L94.1 |
|  |  |  |  |
| **DETERMINATIONS** | | | |
|  |  |  |  |
| 63 & 64/2018 | olecranon bursitis | 23/07/2018 | M70.2 |
|  |  |  |  |
| 65 & 66/2018 | knee bursitis | 23/07/2018 | M70.4 or M70.5 |
|  |  |  |  |
| **AMENDMENTS** | | | |
|  |  |  |  |
| 67 & 68/2018 | lumbar spondylosis | 23/07/2018 | N/A |
|  |  |  |  |
| 69 & 70/2018 | thoracic spondylosis | 23/07/2018 | N/A |
|  |  |  |  |

| **SUMMARY OF CHANGES** | | |
| --- | --- | --- |
| 53 & 54/2018 | bipolar disorder | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *bipolar disorder* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 53/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'bipolar disorder' in subsection 7(2); * revising the factor in subsection 9(1)(a) concerning 'a category 1A stressor', by inclusion of a note, now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(1)(b) concerning 'a category 1B stressor', by inclusion of a note, now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(1)(c) concerning 'a category 2 stressor', by inclusion of a note, now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(1)(d) concerning 'death of a significant other', by inclusion of a note, now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(1)(e) concerning 'death from suicide of a close family member', by inclusion of a note, now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(1)(f) concerning 'being within 90 days postpartum', now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(1)(g) concerning 'alcohol use disorder or substance use disorder', for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(1)(h) concerning 'a disorder of mental health', for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(1)(i) concerning 'having insomnia', for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(1)(j) concerning 'concussion or moderate to severe traumatic brain injury', for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(2)(a) concerning 'taking a drug, or a drug from a class of drugs', now for substance/medication-induced bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(2)(b) concerning 'taking a drug which is associated in the individual with the development of symptoms of bipolar disorder', now for substance/medication-induced bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(2)(c) concerning 'antidepressant drug therapy' by the inclusion of 'antiepileptic drug therapy', now for substance/medication-induced bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(2)(d) concerning 'alcohol use disorder or substance use disorder', for substance/medication-induced bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(2)(e) concerning 'caffeine', for substance/medication-induced bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(2)(f) concerning 'a specified organic solvent', for substance/medication-induced bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(3) concerning 'an endocrine, cardiovascular, respiratory, metabolic, infectious or neurological disorder', for bipolar and related disorder due to another medical condition only, for clinical onset only; * revising the factor in subsection 9(4) concerning 'a category 1A stressor', by inclusion of a note, for clinical worsening; * revising the factor in subsection 9(5) concerning 'a category 1B stressor', by inclusion of a note, for clinical worsening; * revising the factor in subsection 9(6) concerning 'a category 2 stressor', by inclusion of a note, for clinical worsening; * revising the factor in subsection 9(7) concerning 'death of a significant other', by inclusion of a note, for clinical worsening; * revising the factor in subsection 9(8) concerning 'death from suicide of a close family member', by inclusion of a note, for clinical worsening; * new factor in subsection 9(10) concerning 'a disorder of mental health', for clinical worsening; * new factor in subsection 9(11) concerning 'taking a drug, or a drug from a class of drugs', for clinical worsening; * revising the factor in subsection 9(12) concerning 'taking a drug which is associated in the individual with the worsening of symptoms of bipolar disorder', for clinical worsening; * revising the factor in subsection 9(13) concerning 'antidepressant drug therapy' by the inclusion of 'antiepileptic drug therapy', for clinical worsening; * revising the factor in subsection 9(14) concerning 'a medical condition', by inclusion of a note, for clinical worsening; * revising the factor in subsection 9(15) concerning 'severe childhood abuse', for clinical worsening; * new factor in subsection 9(17) concerning 'having insomnia', for clinical worsening; * revising the factor in subsection 9(18) concerning 'electroconvulsive therapy', for clinical worsening; * revising the factor in subsection 9(19) concerning 'bright light therapy', for clinical worsening; * new factor in subsection 9(20) concerning 'concussion or moderate to severe traumatic brain injury', for clinical worsening; * new factor in subsection 9(21) concerning 'deep brain stimulation', for clinical worsening; * new factor in subsection 9(22) concerning 'vagus nerve stimulation', for clinical worsening; * new factor in subsection 9(23) concerning 'caffeine', for clinical worsening; * deleting the factors concerning 'drug dependence or drug abuse' and 'alcohol dependence or alcohol abuse' as they are now covered by the factor in subsection 9(1)(g) concerning 'alcohol use disorder or substance use disorder' for clinical onset, and the factor in subsection 9(10) concerning 'a disorder of mental health' for clinical worsening; * deleting the factors concerning 'a clinically significant anxiety spectrum disorder' as they are now covered by the factors in subsections 9(1)(h) & 9(10) concerning 'a disorder of mental health'; * new definitions of 'bipolar and related disorder due to another medical condition', 'corpse', 'cyclothymic disorder', 'DSM-5', 'hypomanic episode', 'insomnia as specified', 'major depressive episode', 'major depressive episode with mixed features', 'manic episode', 'medical condition is a direct physiological cause of the mood symptoms', 'MRCA', 'organic solvents', 'other specified bipolar and related disorder and unspecified bipolar and related disorder', 'specified list of drugs', 'Specified List 1 of clinically significant disorders of mental health', 'Specified List 2 of clinically significant disorders of mental health', 'specified organic solvent', 'substance/medication-induced bipolar and related disorder' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'bipolar I disorder', 'bipolar II disorder', 'category 1A stressor', 'category 1B stressor', 'category 2 stressor', 'eyewitness', 'inhalants', 'medical condition as specified' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a clinically significant anxiety spectrum disorder', 'a drug from the class of drugs in specified list 1', 'a drug from the class of drugs in specified list 3', 'a drug in specified list 2', 'a drug in specified list 4', ' bipolar disorder not otherwise specified', 'cyclothymia', 'DSM-IV-TR', 'mood disorder due to a general medical condition with manic or mixed features', 'substance-induced mood disorder with manic or mixed features' and 'the general medical condition is a direct physiological cause of the mood symptoms'.   ***For BoP SoP*** ***(Instrument No. 54/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'bipolar disorder' in subsection 7(2); * revising the factor in subsection 9(1)(a) concerning 'a category 1A stressor', by inclusion of a note, now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(1)(b) concerning 'a category 1B stressor', by inclusion of a note, now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(1)(c) concerning 'a category 2 stressor', by inclusion of a note, now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(1)(d) concerning 'death of a significant other', by inclusion of a note, now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(1)(e) concerning 'being within 90 days postpartum', now for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(1)(f) concerning 'alcohol use disorder or substance use disorder', for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(1)(g) concerning 'a disorder of mental health', for bipolar I disorder, bipolar II disorder, cyclothymic disorder, major depressive episode with mixed features, other specified bipolar and related disorder and unspecified bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(2)(a) concerning 'taking a drug, or a drug from a class of drugs', now for substance/medication-induced bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(2)(b) concerning 'taking a drug which is associated in the individual with the development of symptoms of bipolar disorder', now for substance/medication-induced bipolar and related disorder only, for clinical onset only; * revising the factor in subsection 9(2)(c) concerning 'antidepressant drug therapy' by the inclusion of 'antiepileptic drug therapy', now for substance/medication-induced bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(2)(d) concerning 'alcohol use disorder or substance use disorder', now for substance/medication-induced bipolar and related disorder only, for clinical onset only; * new factor in subsection 9(3) concerning 'an endocrine, cardiovascular, respiratory, metabolic, infectious or neurological disorder', for bipolar and related disorder due to another medical condition only, for clinical onset only; * revising the factor in subsection 9(4) concerning 'a category 1A stressor', by inclusion of a note, for clinical worsening; * revising the factor in subsection 9(5) concerning 'a category 1B stressor', by inclusion of a note, for clinical worsening; * revising the factor in subsection 9(6) concerning 'a category 2 stressor', by inclusion of a note, for clinical worsening; * revising the factor in subsection 9(7) concerning 'death of a significant other', by inclusion of a note, for clinical worsening; * new factor in subsection 9(9) concerning 'a disorder of mental health', for clinical worsening; * new factor in subsection 9(10) concerning 'taking a drug, or a drug from a class of drugs', for clinical worsening; * revising the factor in subsection 9(11) concerning 'taking a drug which is associated in the individual with the worsening of symptoms of bipolar disorder', for clinical worsening; * revising the factor in subsection 9(12) concerning 'antidepressant drug therapy' by the inclusion of 'antiepileptic drug therapy', for clinical worsening; * revising the factor in subsection 9(13) concerning 'a medical condition', by inclusion of a note, for clinical worsening; * revising the factor in subsection 9(14) concerning 'severe childhood abuse', for clinical worsening; * revising the factor in subsection 9(16) concerning 'electroconvulsive therapy', for clinical worsening; * revising the factor in subsection 9(17) concerning 'bright light therapy', for clinical worsening; * new factor in subsection 9(18) concerning 'deep brain stimulation', for clinical worsening; * new factor in subsection 9(19) concerning 'vagus nerve stimulation', for clinical worsening; * deleting the factors concerning 'drug dependence or drug abuse' and 'alcohol dependence or alcohol abuse' as they are now covered by the factor in subsection 9(1)(f) concerning 'alcohol use disorder or substance use disorder' for clinical onset, and the factor in subsection 9(9) concerning 'a disorder of mental health' for clinical worsening; * deleting the factors concerning 'a clinically significant anxiety spectrum disorder' as they are now covered by the factors in subsections 9(1)(g) & 9(9) concerning 'a disorder of mental health'; * new definitions of 'bipolar and related disorder due to another medical condition', 'corpse', 'cyclothymic disorder', 'DSM-5', 'hypomanic episode', 'major depressive episode', 'major depressive episode with mixed features', 'manic episode', 'medical condition is a direct physiological cause of the mood symptoms', 'MRCA', 'other specified bipolar and related disorder and unspecified bipolar and related disorder', 'specified list of drugs', 'Specified List 1 of clinically significant disorders of mental health', 'Specified List 2 of clinically significant disorders of mental health', 'substance/medication-induced bipolar and related disorder' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'bipolar I disorder', 'bipolar II disorder', 'category 1A stressor', 'category 1B stressor', 'category 2 stressor', 'eyewitness', 'medical condition as specified' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a clinically significant anxiety spectrum disorder', 'a drug from the class of drugs in specified list 1', 'a drug from the class of drugs in specified list 3', 'a drug in specified list 2', 'a drug in specified list 4', 'bipolar disorder not otherwise specified', 'cyclothymia', 'DSM-IV-TR', 'mood disorder due to a general medical condition with manic or mixed features', 'substance-induced mood disorder with manic or mixed features' and 'the general medical condition is a direct physiological cause of the mood symptoms'.   **The determining of these Instruments finalises the investigation in relation to *bipolar disorder* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 55 & 56/2018 | panic disorder | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *panic disorder* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 55/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'panic disorder' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factors in subsections 9(1) & 9(13) concerning 'a category 1A stressor', by inclusion of a note; * revising the factors in subsections 9(2) & 9(14) concerning 'a category 1B stressor', by inclusion of a note; * revising the factor in subsection 9(3) concerning 'severe childhood abuse', by inclusion of a note, for clinical onset; * revising the factors in subsections 9(4) & 9(16) concerning 'death of a significant other'; * revising the factors in subsections 9(5) & 9(17) concerning 'a clinically significant disorder of mental health'; * new factors in subsections 9(6) & 9(18) concerning 'sleep apnoea'; * revising the factors in subsections 9(7) & 9(19) concerning 'a medical illness or injury'; * new factors in subsections 9(8) & 9(20) concerning 'a severe, chronic medical condition'; * new factors in subsections 9(9) & 9(21) concerning 'concussion or moderate to severe traumatic brain injury'; * new factors in subsections 9(11) & 9(23) concerning 'a category 2 stressor'; * new factors in subsections 9(12) & 9(24) concerning 'migraine'; * new factor in subsection 9(15) concerning 'severe childhood abuse', for clinical worsening; * deleting the factor concerning 'a moderate to severe cerebral trauma' as it is now covered by the factor in subsection 9(9) concerning 'concussion or moderate to severe traumatic brain injury', for clinical onset, and is also now included for clinical worsening in the factor in subsection 9(21); * new definitions of 'category 2 stressor', 'corpse', 'DSM-5', 'MRCA' 'severe, chronic medical condition' and 'VEA' in Schedule 1 - Dictionary; * revising the definitions of 'category 1A stressor', 'category 1B stressor', 'clinically significant disorder of mental health from Specified List 1', 'clinically significant disorder of mental health from Specified List 2' and 'relevant service' in Schedule 1 - Dictionary; and * deleting the definition of 'moderate to severe cerebral trauma'.   ***For BoP SoP*** ***(Instrument No. 56/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'panic disorder' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factors in subsections 9(1) & 9(12) concerning 'a category 1A stressor', by inclusion of a note; * revising the factors in subsections 9(2) & 9(13) concerning 'a category 1B stressor', by inclusion of a note; * revising the factor in subsection 9(3) concerning 'severe childhood abuse', by inclusion of a note, for clinical onset; * revising the factors in subsections 9(4) & 9(15) concerning 'death of a significant other'; * revising the factors in subsections 9(5) & 9(16) concerning 'a clinically significant disorder of mental health'; * new factors in subsections 9(6) & 9(17) concerning 'sleep apnoea'; * revising the factors in subsections 9(7) & 9(18) concerning 'a medical illness or injury'; * new factors in subsections 9(8) & 9(19) concerning 'a severe, chronic medical condition'; * new factors in subsections 9(9) & 9(20) concerning 'concussion or moderate to severe traumatic brain injury'; * new factors in subsections 9(11) & 9(22) concerning 'a category 2 stressor'; * new factor in subsection 9(14) concerning 'severe childhood abuse', for clinical worsening; * new definitions of 'category 2 stressor', 'corpse', 'DSM-5', 'MRCA' 'severe, chronic medical condition' and 'VEA' in Schedule 1 - Dictionary; and * revising the definitions of 'category 1A stressor', 'category 1B stressor', 'clinically significant disorder of mental health from Specified List 1', 'clinically significant disorder of mental health from Specified List 2' and 'relevant service' in Schedule 1 - Dictionary.   **The determining of these Instruments finalises the investigation in relation to *panic disorder* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 57 & 58/2018 | cluster headache | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *cluster headache* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 57/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'cluster headache' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning 'trauma to the skull or face', for clinical onset only; * new factor in subsection 9(2) concerning 'concussion or moderate to severe traumatic brain injury', for clinical onset only; * new factor in subsection 9(3) concerning 'eye exenteration', for clinical onset only; * new factors in subsections 9(4) & 9(7) concerning 'sleep apnoea'; * new factors in subsections 9(5) & 9(8) concerning 'smoking'; * new factor in subsection 9(6) concerning 'using intranasal cocaine', for clinical onset only; * revising the factor in subsection 9(9) concerning 'taking glyceryl trinitrate, isosorbide mononitrate or isosorbide dinitrate', for clinical worsening only; * new factor in subsection 9(10) concerning 'consuming alcohol', for clinical worsening only; * new factor in subsection 9(11) concerning 'being treated with sildenafil', for clinical worsening only; * deleting the factor concerning 'trauma to the forehead, temple, or eye socket' as it is now covered by the factor in subsection 9(1) concerning 'trauma to the skull or face'; * new definitions of 'exenteration', 'MRCA', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products', 'trauma to the skull or face' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' in Schedule 1 - Dictionary; and * deleting the definition of 'trauma to the forehead, temple, or eye socket'.   ***For BoP SoP*** ***(Instrument No. 58/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'cluster headache' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factor in subsection 9(1) concerning 'taking glyceryl trinitrate, isosorbide mononitrate or isosorbide dinitrate', for clinical worsening only; * new factor in subsection 9(2) concerning 'consuming alcohol', for clinical worsening only; * new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and * revising the definition of 'relevant service' in Schedule 1 – Dictionary.   **The determining of these Instruments finalises the investigation in relation to *cluster headache* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 59 & 60/2018 | Macular degeneration | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *macular degeneration* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 59/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'macular degeneration' in subsection 7(2); * revising the factors in subsections 9(1) & 9(10) concerning 'smoking'; * new factors in subsections 9(2) & 9(11) concerning 'being exposed to second-hand smoke'; * revising the factors in subsections 9(3) & 9(12) concerning 'alcohol'; * new factors in subsections 9(5) & 9(14) concerning 'chronic kidney disease'; * new factors in subsections 9(6) & 9(15) concerning 'abnormal lipid profile'; * new factors in subsections 9(7) & 9(16) concerning 'diabetes mellitus'; * new factors in subsections 9(8) & 9(17) concerning 'hypertension'; * revising the factors in subsections 9(9) & 9(18) concerning 'cataract surgery', as they are now for wet macular degeneration only; * revising the factor in subsection 9(19) concerning 'anticoagulant therapy or thrombolytic therapy', as it is now for wet macular degeneration manifesting as subretinal haemorrhage only, for clinical worsening only; * deleting the factor concerning 'being in an atmosphere with a visible tobacco smoke haze', for clinical onset only, as it is now covered by the factors in subsections 9(2) & 9(11) concerning 'being exposed to second-hand smoke', for clinical onset and clinical worsening; * deleting the factor concerning 'anticoagulant therapy or thrombolytic therapy' for clinical onset only; * new definitions of 'an abnormality of kidney structure or function', 'being exposed to second-hand smoke', 'BMI', 'chronic kidney disease', 'early macular degeneration', 'late macular degeneration', 'lipid profile as specified', 'MRCA', 'VEA' and 'wet macular degeneration' in Schedule 1 - Dictionary; * revising the definitions of 'being obese', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'relevant service' in Schedule 1- Dictionary; and * deleting the definition of 'moderate to severe chronic renal failure'.   ***For BoP SoP*** ***(Instrument No. 60/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'macular degeneration' in subsection 7(2); * revising the factors in subsections 9(1) & 9(5) concerning 'smoking'; * revising the factors in subsections 9(2) & 9(6) concerning 'alcohol'; * new factors 9(3) & 9(7) concerning 'being obese'; * new factors in subsections 9(4) & 9(8) concerning 'chronic kidney disease'; * revising the factor in subsection 9(9) concerning 'anticoagulant therapy or thrombolytic therapy', as it is now for wet macular degeneration manifesting as subretinal haemorrhage only, for clinical worsening only; * deleting the factor concerning 'anticoagulant therapy or thrombolytic therapy', for clinical onset only; * deleting the factors concerning 'cataract surgery'; * new definitions of 'an abnormality of kidney structure or function', 'being obese', 'BMI', 'chronic kidney disease', 'early macular degeneration', 'late macular degeneration', 'MRCA', 'VEA' and 'wet macular degeneration' in Schedule 1 - Dictionary; and * revising the definitions of 'pack-years of cigarettes, or the equivalent thereof in other tobacco products' and 'relevant service' in Schedule 1- Dictionary.   On 13 February 2018, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding these proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors relating to ***anticoagulant therapy or thrombolytic therapy*** and ***cataract surgery***. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. No changes were made to the proposed Instruments following this consultation process.  **The determining of these Instruments finalises the investigation in relation to *macular degeneration* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 61 & 62/2018 | localised sclerosis | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *localised sclerosis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.  The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:  ***For RH SoP*** ***(Instrument No. 61/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'localised sclerosis' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factors in subsections 9(2) & 9(5) concerning 'being treated with a drug'; * revising the factors in subsections 9(3) & 9(6) concerning 'a course of therapeutic radiation'; * new factor in subsection 9(4) concerning 'injury to the skin'; * deleting the factor concerning 'silica dust', for clinical worsening only; * deleting the factors concerning 'chronic graft versus host disease'; * deleting the factors concerning 'trichloroethylene'; * deleting the factors concerning 'gaseous vinyl chloride'; * new definitions of 'injury to the skin', 'MRCA', 'specified list of drugs' and 'VEA' in Schedule 1 - Dictionary; * revising the definition of 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a course of therapeutic radiation' and 'a drug from the specified list'.   ***For BoP SoP*** ***(Instrument No. 62/2018)***   * adopting the latest revised Instrument format, which commenced in 2015; * specifying a day of commencement for the Instrument in section 2; * revising the definition of 'localised sclerosis' in subsection 7(2); * revising the reference to 'ICD-10-AM code' in subsection 7(4); * revising the factors in subsections 9(1) & 9(3) concerning 'being treated with a drug'; * revising the factors in subsections 9(2) & 9(4) concerning 'a course of therapeutic radiation'; * deleting the factors concerning 'silica dust'; * deleting the factors concerning 'chronic graft versus host disease'; * deleting the factors concerning 'trichloroethylene'; * deleting the factors concerning 'gaseous vinyl chloride'; * new definitions of 'MRCA', 'specified list of drugs' and 'VEA' in Schedule 1- Dictionary; * revising the definition of 'relevant service' in Schedule 1 - Dictionary; and * deleting the definitions of 'a course of therapeutic radiation' and 'a drug from the specified list'.   On 13 February 2018 and 11 May 2018, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. These correspondence emphasised the deletion of factors relating to ***silica dust, chronic graft versus host disease, trichloroethylene*** and ***gaseous vinyl chloride***. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. No changes were made to the proposed Instruments following this consultation process.  **The determining of these Instruments finalises the investigation in relation to *localised sclerosis* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 63 & 64/2018 | olecranon bursitis | **New Condition**  **The determining of these new Instruments finalises the investigation in relation to *olecranon bursitis* as advertised in the Government Notices Gazette of 23 January 2018.** |
| 65 & 66/2018 | knee bursitis | **New Condition**  **The determining of these new Instruments finalises the investigation in relation to *knee bursitis* as advertised in the Government Notices Gazette of 23 January 2018.** |
| 67 & 68/2018 | lumbar spondylosis | **Amendment**  These instruments amend Statements of Principles Nos. 62 & 63 of 2014 concerning ***lumbar spondylosis*** by:  ***For RH SoP*** ***(Instrument No. 67/2018)***   * specifying a day of commencement for the Instrument in section 3; * replacing the existing factors "(j)" and "(y)" in clause 6 concerning 'lifting loads'; and * replacing the existing factors "(k)" and "(z)" in clause 6 concerning 'carrying loads'.   ***For BoP SoP*** ***(Instrument No. 68/2018)***   * specifying a day of commencement for the Instrument in section 3; * replacing the existing factors "(i)" and "(x)" in clause 6 concerning 'lifting loads'; and * replacing the existing factors "(j)" and "(y)" in clause 6 concerning 'carrying loads'.   **The determining of these Instruments finalise the investigation in relation to *lumbar spondylosis* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 69 & 70/2018 | thoracic spondylosis | **Amendment**  These instruments amend Statements of Principles Nos. 64 & 65 of 2014 concerning ***thoracic spondylosis*** by:  ***For RH SoP*** ***(Instrument No. 69/2018)***   * specifying a day of commencement for the Instrument in section 3; * replacing the existing factors "(i)" and "(u)" in clause 6 concerning 'lifting loads'; and * replacing the existing factors "(j)" and "(v)" in clause 6 concerning 'carrying loads'.   ***For BoP SoP*** ***(Instrument No. 70/2018)***   * specifying a day of commencement for the Instrument in section 3; * replacing the existing factors "(h)" and "(t)" in clause 6 concerning 'lifting loads'; and * replacing the existing factors "(i)" and "(u)" in clause 6 concerning 'carrying loads'.   **The determining of these Instruments finalise the investigation in relation to *thoracic spondylosis* as advertised in the Government Notices Gazette of 14 November 2017.** |